About 1 in 4 people with Graves' disease who stop taking potassium iodide while on methimazole will see their thyroid hormone levels rise again within a few weeks, showing that stopping potassium iodide without monitoring can often lead to treatment failure.
Claim Context
Approximately 23.3% of drug-naïve patients with Graves' disease treated with methimazole and potassium iodide experience thyroid hormone rebound (elevated free T3 and/or T4) within 4–8 weeks after potassium iodide discontinuation, indicating a substantial risk of treatment failure if discontinuation is not guided by specific biomarkers.
“In 35 of 150 patients (23.3%), the levels of free T3 and/or free T4 were elevated beyond the upper limit of each reference range after cessation of KI.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether the 23.3% rebound rate is generalizable across global populations and different KI dosing protocols.
A systematic review and meta-analysis of all published cohort studies reporting incidence of thyroid hormone rebound after KI discontinuation in Graves' disease, pooling data by region, KI dose, and baseline T4 levels.
Whether the incidence of rebound differs between KI discontinuation strategies (e.g., fixed timing vs. biomarker-guided).
A multicenter RCT comparing 300 patients randomized to fixed KI discontinuation at 8 weeks vs. biomarker-guided discontinuation (free T3 ≤3.2 pg/mL and KI/MMI ≤1.7), with primary outcome: rebound incidence at 6 weeks.
Whether the 23.3% rebound rate is reproducible in a larger, more diverse population.
A prospective multicenter cohort study of 1000+ drug-naïve Graves' patients initiating KI/MMI, with standardized KI discontinuation timing and measurement of free T3/T4 at 4–8 weeks to confirm rebound incidence.
Whether rebound cases differ from non-rebound cases in baseline characteristics.
A case-control study comparing 200 patients with rebound to 200 without, assessing baseline TRAb, T4, thyroid volume, and KI/MMI initiation timing to identify predictors of rebound.
Whether rebound incidence correlates with KI duration or baseline severity in a single snapshot.
A cross-sectional survey of 500 Graves' patients who had previously discontinued KI, asking about timing and symptoms, and measuring current thyroid function to estimate historical rebound rate.